Red/NIR emissive aggregation‐induced emission‐active photosensitizers with strong donor–acceptor strength for image‐guided photodynamic therapy of cancer
Luminescence · 2023
DOI: 10.1002/bio.4599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Luminescence, 2023. Verfasst von Yucheng Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Light Industry and Chemical Engineering College, Guangdong University of Technology, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Photochemotherapy, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Research Grants Council of Hong Kong, National Outstanding Youth Science Fund Project of National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Light‐mediated therapies such as photodynamic therapy (PDT) are considered emerging cancer treatment strategies. However, there are still lots of defect with common photosensitizers (PSs), such as short emission wavelength, weak photostability, poor cell permeability, and low PDT efficiency. Therefore, it is very important to develop high‐performance PSs. Recently, luminogens with aggregation‐induced emission (AIE) characteristics and red/near‐infrared (NIR) emissive have been reported as promising PSs for image‐guided cancer therapy, due to them being able to prevent autofluorescence in physiological environments, their enhanced fluorescence in the aggregated state, and generation of reactive oxygen species (ROS). Herein, we developed PSs named TBTCPM and MTBTCPM with donor–acceptor (D–A) structures, strong red/NIR, excellent targeting specificities to good cell permeability, and high photostability. Interestingly, both of them can efficiently generate ROS under white light irradiation and possess excellent killing effect on cancer cells. This study, thus, not only demonstrates applications in cell image‐guided PDT cancer therapy performances but also provides strategy for construction of AIEgens with long emission wavelengths.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Light Industry and Chemical Engineering College, Guangdong University of Technology, Guangzhou, Guangdong, China.
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, The Hong Kong University of Science and Technology, Hong Kong, China.
- School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
ORCID-Profile: Yucheng Ma
Förderung
- Research Grants Council of Hong Kong
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Innovation and Technology Commission
- Shenzhen Key Laboratory of Functional Aggregate Materials
- Science, Technology and Innovation Commission of Shenzhen Municipality
Zitieren
APA
Ma, Y., Yin, W., Ji, S., Wang, J., Lam, J. W. Y., Kwok, R. T. K., Huo, Y., Sun, J., & Tang, B. Z. (2023). Red/NIR emissive aggregation‐induced emission‐active photosensitizers with strong donor–acceptor strength for image‐guided photodynamic therapy of cancer. Luminescence. https://doi.org/10.1002/bio.4599
Vancouver
Ma Y, Yin W, Ji S, Wang J, Lam JWY, Kwok RTK, et al. Red/NIR emissive aggregation‐induced emission‐active photosensitizers with strong donor–acceptor strength for image‐guided photodynamic therapy of cancer. Luminescence. 2023. doi:10.1002/bio.4599
BibTeX
@article{Ma2023,
author = {Ma, Yucheng and Yin, Weidong and Ji, Shaomin and Wang, Jin and Lam, Jacky Wing Yip and Kwok, Ryan Tsz Kin and Huo, Yanping and Sun, Jianwei and Tang, Ben Zhong},
title = {Red/NIR emissive aggregation‐induced emission‐active photosensitizers with strong donor–acceptor strength for image‐guided photodynamic therapy of cancer},
journal = {Luminescence},
year = {2023},
doi = {10.1002/bio.4599}
}
EUVIMED